Recently, a number of Chinese listed IVD companies released 2020 annual performance report, disclosing their revenue. Driven by the demand of testing products of COVID-19, the performance growth is very gratifying.

DaAn Gene released a performance report on the evening of February 25. The 2020 annual total revenue was 5.345 billion yuan, a year-on-year increase of 386.7%; net profit was 2.433 billion yuan, a year-on-year increase of 2539.66%; basic earnings per share were 2.77 yuan. Influenced by the COVID-19 epidemic, the market demand for Novel Coronavirus (2019-NCoV) nucleic acid detection kits and nucleic acid detection instruments and related consumable materials has increased significantly, which has had a positive impact on the company's performance.

Sansure released the results of the report on the evening of February 25. The 2020 annual total revenue was 4.767 billion yuan, a year-on-year growth of 1205.67%; Net profit returned to the parent reached 2.616 billion yuan, a year-on-year growth of 6526%. The products developed by the company have better met market demand. The sales performance of products and services such as COVID-19 nucleic acid detection reagents, nucleic acid detection instruments, related consumables, inspection services, etc. has made major breakthroughs. At the same time, the company's instrument sales and installed capacity growth further drove the company's incremental sales of reagents across the entire line. In 2020, the company shipped 6,122 instruments in total, which can continue to leverage the advantages and accelerate the increase in the market share of the entire line of products.

Maccura released a performance report on the evening of February 25. The 2020 annual total revenue was 3.704 billion yuan, a year-on-year increase of 14.91%; net profit of 795 million yuan, a year-on-year increase of 51.43%; basic earnings per share of 1.4303 yuan. The company's novel crown detection product sale of molecular diagnostics and rapid detection platform had grown rapidly. At the same time, with the continuous consolidation of epidemic prevention and control results in China, the company's sales of normal testing products have steadily recovered.

Liferiver released a performance report on the evening of February 24. In 2020, the 2020 annual total revenue was 2.051 billion yuan, an increase of 692.47% year-on-year; net profit was 928 million yuan, an increase of 1701.53% year-on-year; basic earnings per share were 6.36 yuan. During the reporting period, the company was one of the first companies to obtain the registration certificate for the novel corona virus nucleic acid detection kit. The sales scale of the novel corona virus nucleic acid detection kit achieved a major breakthrough, and it also drove the incremental sales of other related series of products such as molecular diagnostic instruments and nucleic acid extraction reagents. So the company's overall sales scale and performance in 2020 showed a substantial increase.